Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CASR | P41180 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29847698 | 1.00 | TSHR (0.70) | TSHRMAPK1KDM4ELMNAMTNR1A | |
| SCHEMBL1241813 | 0.92 | LMNA (0.73) | TSHRMAPK1KDM4ELMNAMTNR1A | |
| SCHEMBL4045516 | 0.89 | LMNA (0.59) | TSHRMAPK1KDM4ELMNAMTNR1A | |
| SCHEMBL4724285 | 0.85 | LMNA (0.53) | TSHRMAPK1KDM4ELMNAMTNR1A | |
| SCHEMBL5786398 | 0.85 | MAPK1 (0.64) | TSHRMAPK1KDM4ELMNAMTNR1A | |
| SCHEMBL2477290 | 0.84 | MAPK1 (0.68) | TSHRMAPK1KDM4ELMNAMTNR1A | |
| SCHEMBL23639147 | 0.82 | LMNA (0.59) | TSHRMAPK1KDM4ELMNAMTNR1A | |
| SCHEMBL13572916 | 0.82 | TSHR (0.76) | TSHRMAPK1KDM4EMTNR1AMTNR1B | |
| SCHEMBL11272514 | 0.81 | MAPK1 (0.60) | TSHRMAPK1KDM4ELMNAMTNR1A | |
| SCHEMBL7510305 | 0.81 | LMNA (0.63) | TSHRMAPK1KDM4ELMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250305931-A1 | METHOD FOR ANALYZING A URINE SAMPLE, AND A REAGENT FOR ANALYZING A URINE SAMPLE | SYSMEX CORPORATION (JP) | 2025-10-02 | — | — | US | claimed |
| EP-4624926-A1 | A METHOD FOR ANALYZING A URINE SAMPLE, AND A REAGENT FOR ANALYZING A URINE SAMPLE | SYSMEX CORPORATION (JP) | 2025-10-01 | — | — | EP | claimed |
| CN-115385960-A | Preparation method and application of oxaspiro compound with large steric hindrance | 惠州凯特立斯科技有限公司 | 2022-11-25 | — | — | CN | claimed |
| EP-0221293-B1 | 7,8,9,10-Tetrahydro-6-oxo-6H-dibenzo[b,d]pyranyloxy-propanes | PENNWALT CORPORATION (US) | 1989-03-08 | — | — | EP | claimed |
| US-20250305931-A1 | METHOD FOR ANALYZING A URINE SAMPLE, AND A REAGENT FOR ANALYZING A URINE SAMPLE | SYSMEX CORPORATION (JP) | 2025-10-02 | — | — | US | disclosed |
| US-20250305931-A1 | METHOD FOR ANALYZING A URINE SAMPLE, AND A REAGENT FOR ANALYZING A URINE SAMPLE | SYSMEX CORPORATION (JP) | 2025-10-02 | — | — | US | disclosed |
| EP-4624926-A1 | A METHOD FOR ANALYZING A URINE SAMPLE, AND A REAGENT FOR ANALYZING A URINE SAMPLE | SYSMEX CORPORATION (JP) | 2025-10-01 | — | — | EP | disclosed |
| EP-4624926-A1 | A METHOD FOR ANALYZING A URINE SAMPLE, AND A REAGENT FOR ANALYZING A URINE SAMPLE | SYSMEX CORPORATION (JP) | 2025-10-01 | — | — | EP | disclosed |
| CN-115385960-A | Preparation method and application of oxaspiro compound with large steric hindrance | 惠州凯特立斯科技有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220035216-A1 | ELECTROCHROMIC ELEMENT, AND METHOD FOR DRIVING THE SAME | RICOH COMPANY, LTD. (JP) | 2022-02-03 | — | — | US | disclosed |
| CN-109641831-B | Monomers, polymers, preparation method and use thereof | 东莞东阳光医疗智能器件研发有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-7906667-B2 | Method for producing optically active alcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-15 | — | — | US | disclosed |
| EP-1982972-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-7071180-B2 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM AB (SE) | 2006-07-04 | — | — | US | disclosed |
| EP-1178973-B1 | PYRAZINYL-PIPERAZINE- COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2005-12-21 | — | — | EP | disclosed |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | BIOVITRUM, AB, A STOCKHOLM, SWEDEN CORPORATION | 2003-05-15 | — | — | US | disclosed |
| US-6465467-B1 | DISEASES RELATED TO THE 5-HT2C RECEPTOR, ESPECIALLY EATING, MEMORY, MOOD, URINARY AND ANXIETY DISORDERS, SCHIZOPHRENIA, PAIN, SEXUAL DYSFUNCTIONS | BIOVITRUM AB (SE) | 2002-10-15 | — | — | US | disclosed |
| EP-1178973-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia AB (SE) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000076984-A2 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | BIOVITRUM AB (SE) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092694-A1 | Certain arylaliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases | HTR2C, HTR3C, HTR2A | TSHR 457/4885MAPK1 4034/4885KDM4E 2431/4885 |
| US-20040242554-A1 | CERTAIN ARYLALIPHATIC AND HETEROARYL-ALIPHATIC PIPERAZINYL PYRAZINES AND THEIR USE IN THE TREATMENT OF SEROTONIN-RELATED DISEASES | HTR2C, HTR3C, HTR2A | TSHR 531/4885MAPK1 4042/4885KDM4E 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.